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Expression of d-opioid receptors in sensory neurons is controversial. In this issue of Neuron, Bardoni et al.
(2014) present evidence that DOPrs are expressed on mechanosensory neurons involved in detecting
nonnoxious touch but are very sparse in m-opioid receptor-rich nociceptive neurons.The analgesic actions of m-opioid re-
ceptor (MOPr) drugs on thermal and
mechanical pain-sensing primary afferent
neurons are well known. The selective
expression of MOPr in small, unmyelin-
ated nociceptive neurons (Scherrer et al.,
2009; Heinke et al., 2011) nicely explains
why MOPr-selective opioid drugs relieve
pain with little disruption of other soma-
tosensory modalities. By contrast, the
location and function of d-opioid re-
ceptors (DOPr) in sensory systems are
controversial. The controversy centers
on the extent to which DOPr is coex-
pressed with MOPr in thermal nocicep-
tors (Guan et al., 2005; Wang et al.,
2010; He et al., 2011) versus selective
expression in mechanosensory neurons.
Resolving this is crucial for understanding
the role of endogenous opioid systems
in pain and other sensory processes, as
well as for potential therapeutic develop-
ment of novel opioid drugs that interact
selectively with DOPr or hetero-oligomers
between MOPr and DOPr (Fujita et al.,
2014). In this issue of Neuron, Bardoni
et al. (2014) present convincing ana-
tomical and physiological evidence that
DOPr is expressed predominantly by neu-
rons involved in cutaneous nonnoxious
mechanosensation. Bardoni et al. (2014)
have greatly strengthened the previous
conclusion (Scherrer et al., 2009) that
DOPr is rarely expressed by the MOPr-
rich, small C fiber neurons that are likely
to be nociceptors. They used a transgenic
DOPr-eGFPmouse combined with exten-
sive immunohistochemical classification
of sensory types in dorsal root ganglion
(DRG) and skin, a functional skin-nerve
preparation, and DRG cellular and spinal
synaptic physiology to provide compel-
ling evidence that DOPrs are expressed
by defined classes of low-threshold1220 Neuron 81, March 19, 2014 ª2014 Elsemechanoreceptors (LTMRs). The con-
clusions are clear and finding DOPr on
a range of mechanosensory neurons is
not surprising because it was previously
predicted from the distribution of DOPr
mRNA in NF200 DRG neurons in rodents
and humans (Mennicken et al., 2003).
Moreover, Minami et al. (1995) found
that only a small proportion (5%) of
small C fiber substance P (SP)-express-
ing neurons contained DOPr mRNA by
double in situ hybridization. However,
the new findings place the expression of
DOPr firmly in the domain of light touch
(Figure 1).
There is already extensive evidence
that noxious heat and mechanical stimuli
are processed by distinct populations of
primary afferent fibers (Cavanaugh et al.,
2009; Abrahamsen et al., 2008; Scherrer
et al., 2009), the ‘‘labeled line’’ hypothesis.
Lightly myelinated Ad fibers and nonpep-
tidergic unmyelinated C fibers transmit
noxious mechanical stimuli, while pepti-
dergic C fibers that express SP are acti-
vated by noxious heat. Tuning of primary
afferent neurons also depends on recep-
tor and ion channel expression, their
association with specialized structures
in the skin that detect stimuli, and inte-
gration in the dorsal horn of the spinal
cord (Abraira and Ginty, 2013). Bardoni
et al. (2014) add distinct expression of
DOPr and MOPr in light mechanical
versus thermal nociceptive lines to this.
It is well established that DOPr agonists
inhibit mechanical nociception (Scherrer
et al., 2009) and Bardoni et al. (2014)
make a good case for the potential of
DOPr agonists to treat mechanical allody-
nia in chronic pain states. However, the
extensive expression of DOPr in LTMRs
involved in light touch suggests that
widespread somatosensory side effectsvier Inc.could also be problematic with DOPr
agonists.
The findings of Bardoni et al. (2014) are
at odds with other prominent studies
suggesting that DOPr is expressed in
peptidergic neurons involved in thermal
nociception (Guan et al., 2005; Wang
et al., 2010; He et al., 2011). Scherrer
et al. (2009) foundDOPr-eGFP expression
in SP neurons to be very rare and many of
the previous findings of Guan et al. (2005)
were countered. However, Wang et al.
(2010) reported that DOPr is expressed
in about 70% of small neurons, 30% of
which are SP neurons using in situ hybrid-
ization and single-cell PCR and showed
coexpression of DOPr and MOPr in a
large proportion of DRG neurons using
inhibition of calcium channel currents in
patch-clamp recordings. Other reports
from the same group also provide phar-
macological evidence that DOPr is ex-
pressed in small DRG neurons (Guan
et al., 2005; He et al., 2011). Poor speci-
ficity of DOPr antibodies might explain
some of the discrepancies. Moreover,
the use of very high, nonselective concen-
trations of DOPr agonists by Wang et al.
(2010) and possibly nonselective concen-
trations of antagonists is questionable.
Bardoni et al. (2014) rightly tested
500 nM deltorphin II, a high but most
likely selective concentration, and found
only 1 of 29 neurons responded to both
MOPr and DOPr agonists (including
wild-type mice), rather than the 10 mM
SNC80 used by Wang et al. (2010), which
must be considered nonselective. Other
studies claiming direct DOPr effects
on small DRG neurons have used almost
completely nonselective antagonists
such as DADLE, so they cannot be
considered seriously. To our knowledge,
no other well-controlled pharmacological
Figure 1. Schematic Diagram Illustrating DOPr and MOPr Expression in Cutaneous Sensory
Receptors in Skin
Sensory receptors are arranged according to their DOPr (gray) expression to the left and MOPr (red)
expression on the right. The DOPr-expressing receptors are sensitive to innocuous mechanical stimuli,
such as light touch, while the MOPr nociceptors are stimulated by noxious stimuli. Bardoni et al. (2014)
find a very a small population of peptidergic C fiber nociceptors indicated by ‘‘?’’ that are thought to coex-
press DOPr and MOPr. This is controversial because some groups have reported extensive expression of
DOPr in this population of sensory neurons.
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effects of DOPr agonists in small, pre-
sumed nociceptive DRG neurons or in
the superficial laminae of the spinal dorsal
horn. Poor pharmacological selectivity
and failure to use appropriate antagonist
controls for DOPr agonists in vivo could
also explain many studies that have
claimed involvement of DOPr in thermal
nociception. This problem is clearly evi-
denced by the persistence of analgesia
induced by a range of DOPr agonists in
Oprd1 knockout mice (Kieffer and Gave´r-
iaux-Ruff, 2002). The discrepancies be-
tween Bardoni et al. (2014) and other
methods used by Wang et al. (2010) are
more difficult to explain away. Both
groups used in situ hybridization with con-
tradictory results. One set of results must
be wrong. The discrepancy could be
resolved by testing the two methods in
question in knockout animals. Until the
specificity of themolecular methods is es-
tablished, it will remain uncertain which
research group is right but on balance
the high levels of physiological evidencepresented by Bardoni et al. (2014) are
more convincing.
An alternative interpretation of the find-
ings of Bardoni et al. (2014) and Scherrer
et al. (2009) is that the DOPr-eGFGP is
not found in many peptidergic neurons
because the attachment of eGFP near
the C terminus of the receptor disrupts
the trafficking and/or degradation of
DOPr in SP neurons (Wang et al., 2010).
These authors presented evidence that
this is the case by showing disrupted traf-
ficking of a DOPR-eGFP construct when
transfected into small DRG neurons.
However, Bardoni et al. (2014) have nicely
answered this criticism by showing an
identical distribution of Oprd1 mRNA
using in situ hybridization and electro-
physiology in wild-type mice. It remains
possible that the DOPr-eGFP transgenic
construct is not trafficked in the same
way as the native DOPr, but this is not
important for the findings reported by
Bardoni et al. (2014).
It is important to establish the colocali-
zation of MOPr and DOPr beyond doubtNeuron 81in neurons in pain pathways because
there is growing evidence that these re-
ceptors can exist as hetero-oligomers
and there are novel heteromer-selective
opioid therapeutics currently being devel-
oped (Fujita et al., 2014). Of course, the
two receptors must be coexpressed to
potentially oligomerize and the convincing
evidence of Bardoni et al. (2014) suggests
that MOPr-DOPr hetero-oligomers occur
rarely, if at all, in nociceptive sensory
neurons. Indeed, recent evidence on
colocalization of DOPr-eGFP and MOPr-
mcherry throughout the CNS suggests
that colocalization is very uncommon
but does occur in some pain-related
areas of the brain (Erbs et al., 2014).
The biological significance of segrega-
tion of DOPr and MOPr in sensory affer-
ents is unknown. Under some physiolog-
ical and pathological conditions, both
types of sensory nerves are likely to be
bathed in endogenous opioids that act
on each receptor with similar affinities
(Williams et al., 2001). DOPr and MOPr
produce similar intracellular signals but
upon activation DOPr is trafficked to a
lysosomal degradation pathway, while
MOPr is recycled. Perhaps this property
produces transient suppression of light
mechanical sensation by DOPr because
the receptor is degraded versus pro-
longed inhibition of nociception by MOPr
during sustained episodes of endogenous
opioid release.REFERENCES
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